SGMO News and Press, Sangamo Therapeutics Inc. From 08/04/22

Sangamo Therapeutics press release ( NASDAQ: SGMO ): Q2 GAAP EPS of -$0.29 beats by $0.06 . Revenue of $29.38M (+5.3% Y/Y) beats by $4.75M . Financial Guidance for 2022 Reiterated (initial guidance provided on February 24, 2022). On a GAAP basis, SGMO conti...

Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. “We made meaningful progress advancing our...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2022 financial results after the market closes on Thursday, August 4, 2022. The press release will be followed by a conference call...

The European Commission (EC) granted orphan medicinal product designation to Sangamo Therapeutics' ( NASDAQ: SGMO ) CAR-Treg cell therapy TX200 for treatment in solid organ transplantation. "Our goal with TX200 is to create a transformative therapy that reduc...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Commission (EC) has granted Orphan Medicinal Product Designation (OMPD) to TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy produc...

Wedbush Securities has initiated Sangamo Therapeutics (NASDAQ:SGMO) with a hold rating noting that while it sees promise in isaralgagene civaparvovec for Fabry disease, the candidate needs to demonstrate better durable efficacy and safety compared to current treatments. The firm has a $5 pric...

A group of biotechs focused on gene therapy candidates surged on Tuesday after the FDA posted a favorable review on a β-thalassemia candidate developed by commercial-stage company Bluebird bio (NASDAQ:BLUE) ahead of an AdCom meeting later this week. The data for the marketing applicati...

FTSE Russell has released a preliminary lists of companies set to join or leave the Russell Microcap Index as part of its 2022 annual reconstitution. Notable health care additions include: Inovio Pharma (INO), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), Ocu...

Gainers: Repare Therapeutics  (RPTX) +20%. Credo Technology Group Holding  (CRDO) +8%. Elevation Oncology (ELEV) +8%. MongoDB (MDB) +6%. Global Blood Therapeutics (GBT) +5%. Losers: Charge Enterprises (CRGE) -5%. NerdWallet (NRDS) -5%. Protagonist Therapeutics (PTGX) -5%. ...

Shares of Graphite Bio are down some 85% from their June 2021 IPO pricing, as its first-ever clinical trial for the treatment of sickle cell disease experienced a six-month delay. The company’s potentially curative technology builds on CRISPR Therapeutics by pasting a DNA templ...